Clinical and Translational Science Institute

Projects

Projects per year 2012 2015 2016 2017 2018 2019 2035

• 93 Active
• 217 Finished

Projects per year

Search results

• Finished

  Phase Ib/II study of ALT-803 in combination with gemcita

  Greeno, E. W.

  ALTOR BIOSCIENCE LLC

  10/1/15 → 9/30/19

  Project: Research project

  • Paclitaxel 100%
  • Gemcitabine 100%
  • Pancreas Cancer 100%

• A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AN

  Beckwith, H. C.

  PFIZER, INC.

  9/22/15 → 9/21/19

  Project: Research project

  • Tolerability 100%
  • Solid Malignant Neoplasm 100%

• Phase I, First-Time-in-Human Study of MED/9197, a TLR 71

  Gupta, S.

  MEDIMMUNE, LLC

  9/8/15 → 7/30/20

  Project: Research project

  • Human Study 100%
  • Malignant Neoplasm 50%
  • Solid Malignant Neoplasm 50%

• Endocannabinoids mediate the effect of estradiol on drug

  Peterson, B. M.

  NIH NIDA NATL INST ON DRUG AB

  9/1/15 → 8/1/16

  Project: Research project

  • Diethylstilbestrol 100%
  • Drug 100%
  • Endocannabinoid 100%
  • Drug Dependence 50%

• An Open-Label, Multicenter, Global Phase 2 Basket Study

  Patel, M. R.

  IGNYTA, INC

  9/1/15 → 8/31/23

  Project: Research project

  • Solid 100%
  • Gene Rearrangement 100%
  • ROS1 100%
  • Solid Malignant Neoplasm 100%
  • Entrectinib 100%

• A randomized, open-label phase 2 study of denintuzumab m

  Bachanova, V.

  SEAGEN INC

  9/1/15 → 3/30/20

  Project: Research project

  • Etoposide 100%
  • Diffuse Large B-Cell Lymphoma 100%
  • Patient 100%
  • Chemotherapy 100%
  • Stem Cell Transplant 100%

• Clinical Research Agreement

  Schacker, T. W.

  HENNEPIN HEALTHCARE RESEARCH INSTITUTE

  9/1/15 → 12/31/17

  Project: Research project

• Phase 2, Parallel???Arm Study of MGCD265 in Patients wit

  Patel, M. R.

  MIRATI THERAPEUTICS, INC.

  9/1/15 → 3/14/18

  Project: Research project

  • Lung 100%
  • Genetics 100%
  • Revisions 100%
  • Arm 100%
  • Inpatient 100%

• CITN-06:A Phase 1 Study of the Clinical and Immunologic

  Holtan, S. G.

  FRED HUTCHINSON CANCER CENTER, MELANOMA RESEARCH ALLIANCE

  9/1/15 → 12/30/18

  Project: Research project

  • Cells 100%
  • Interleukin 15 50%
  • Head and Neck Cancer 50%
  • Lung 50%
  • Inpatient 50%

• A Single-arm, Phase 2 Study to Evaluate the Safety and E

  Gupta, S.

  INNOCRIN PHARMACEUTICALS, INC

  9/1/15 → 4/30/19

  Project: Research project

  • Enzalutamide 100%
  • Abiraterone 100%
  • Prostate Cancer 50%
  • Castration Resistant Prostate Cancer 50%

• CITN-06:A Phase 1 Study of the Clinical and Immunologic

  Holtan, S. G.

  FRED HUTCHINSON CANCER CENTER, NIH NATIONAL CANCER INSTITUTE (NCI)

  9/1/15 → 8/31/17

  Project: Research project

  • Cells 100%
  • Interleukin 15 50%
  • Head and Neck Cancer 50%
  • Lung 50%
  • Inpatient 50%

• CITN 11-02: A phase 1 study of recombinant human IL15 (r

  Miller, J. S.

  FRED HUTCHINSON CANCER CENTER, NATIONAL INSTITUTES OF HEALTH (NIH)

  9/1/15 → 8/31/17

  Project: Research project

  • Solid 100%

• A Phase 3, Multicenter, Open-label, Randomized Study of

  Bejanyan, N.

  ASTEX PHARMACEUTICALS, INC

  8/11/15 → 2/28/19

  Project: Research project

  • Combination Therapy 100%
  • Acute Myeloid Leukemia 100%
  • Spontaneous Remission 100%
  • Therapeutic Procedure 100%
  • Adult 100%

• Assessment of Catheter-based Interrogation and Standard

  Raveendran, G.

  ACIST MEDICAL SYSTEMS, INC

  8/3/15 → 9/30/18

  Project: Research project

  • Standards 100%
  • Evaluation 100%
  • Catheter 100%
  • Assessment 100%
  • Measurement 50%

• A Randomized, Open-label, Phase 2 Trial of Ponatinib in

  Warlick, E. D.

  ARIAD PHARMACEUTICALS, INC

  8/1/15 → 10/31/20

  Project: Research project

  • Ponatinib 100%
  • Myeloid Leukemia 50%

• A Phase 2, Open-Label Study of the Safety and Efficacy o

  Bachanova, V.

  INCYTE CORPORATION

  8/1/15 → 8/30/20

  Project: Research project

  • Dezapelisib 100%
  • Hodgkin Disease 50%
  • Itacitinib 50%

• A Phase 3 Open-label, Multicenter, Randomized Study of A

  Warlick, E. D. & Ustun, C.

  ASTELLAS PHARMA, INC

  8/1/15 → 6/30/21

  Project: Research project

  • Acute Myeloid Leukemia 100%
  • Gilteritinib 100%
  • Chemotherapy 100%

• Phase Ib and Phase II Studies of anti-PD-1 Antibody MK-3

  Rao, A. & Gupta, S.

  HOOSIER CANCER RESEARCH NETWORK, INC, MERCK

  8/1/15 → 12/31/20

  Project: Research project

  • Antibody 100%
  • Kidney Metastasis 50%
  • Cancer Research 50%
  • Therapeutic Procedure 50%
  • Bevacizumab 50%

• Phase III, Randomized, Double-Blind, Placebo-Controlled,

  Ottosen, J. M. & Beilman, G. J.

  ATOXBIO, U.S. DEPARTMENT OF HEALTH & HUMAN SVCS

  7/8/15 → 7/30/20

  Project: Research project

  • Placebo 100%
  • Blindness 100%
  • Soft Tissue Infection 33%
  • Group 33%

• :A Randomized Trial Comparing CD3/CD19 Depleted or CD3 D

  Cooley, S. A.

  MILTENYI BIOTEC, INC.

  7/1/15 → 7/30/20

  Project: Research project

  • Combination Therapy 100%
  • Natural Killer Cell 100%
  • Acute Myeloid Leukemia 100%
  • Donor 100%
  • Adult 100%

• A Phase 2, Double-Blind, Randomized Safety And Efficacy

  Afrin, L. B.

  PFIZER, INC.

  7/1/15 → 6/30/16

  Project: Research project

  • Blindness 100%
  • Placebo 50%
  • Myelofibrosis 50%
  • Ruxolitinib 50%
  • Efficacy Study 50%

• A Phase I/1b Study of Enzalutamide in Combination with G

  Gupta, S.

  H. LEE MOFFITT CANCER CENTER & RESEARCH, ASTELLAS PHARMA, INC

  7/1/15 → 6/30/19

  Project: Research project

  • Enzalutamide 100%
  • Bladder Cancer 50%
  • Gemcitabine 50%
  • Cisplatin 50%

• Development of a Culturally Appropriate Diabetes Educati

  Sunni, M.

  CHILDREN'S HOSPITALS & CLINICS OF MN

  7/1/15 → 2/28/18

  Project: Research project

  • Education 100%

• A phase 1B, open label, dose escalation study to evaluat

  Ryan, C. & Gupta, S.

  PFIZER, INC.

  6/22/15 → 6/30/20

  Project: Research project

  • Solid Malignant Neoplasm 100%
  • Pharmacodynamics 100%
  • Pharmacokinetics 100%
  • Crizotinib 100%

• A Multicenter, Open-Label Study to Evaluate the Safety a

  Orza, F. M. & Hutchins, J. L.

  PACIRA PHARMACEUTICALS, INC.

  6/8/15 → 7/24/15

  Project: Research project

  • Bupivacaine 100%

• An International, Multi-Center, Double-Blind, Randomized

  Greeno, E. W.

  IMMUNOMEDICS, INC

  5/12/15 → 12/31/18

  Project: Research project

  • Gemcitabine 100%
  • Blindness 100%
  • Placebo 50%
  • Yttrium 90 50%
  • Clivatuzumab Tetraxetan 50%

• A Phase 2, open-label, single-arm, intra-subject dose-es

  Lazaryan, A.

  ACTELION PHARMACEUTICALS LTD

  5/1/15 → 4/30/19

  Project: Research project

  • Tolerability 100%
  • Biological Activity 100%
  • Ponesimod 100%
  • Pharmacokinetics 100%
  • Label 100%

• An open label, randomized study to determine the rate of

  Madlon-Kay, R.

  THE CLEVELAND CLINIC FOUNDATION, ASTRAZENECA

  5/1/15 → 4/30/16

  Project: Research project

  • Troponin 100%

• A Prospectivem Multicenter, Single Arm Open Label P4 to

  Thenappan, T.

  ACTELION PHARMACEUTICALS LTD

  5/1/15 → 5/1/18

  Project: Research project

  • Pulmonary Hypertension 100%
  • Macitentan 100%
  • Heart Ventricle Remodeling 100%
  • Hypertension 100%
  • Ventricular Remodeling 100%

• An Expanded Access Program for Elotuzumab in Combination

  McClune, B. L.

  BRISTOL-MYERS SQUIBB COMPANY

  5/1/15 → 12/31/16

  Project: Research project

  • Elotuzumab 100%
  • Dexamethasone 100%
  • Lenalidomide 50%
  • Multiple Myeloma 50%

• Novartis CCTL019C2201; HM2015-13: A phase II, single arm

  Bachanova, V.

  NOVARTIS PHARMACEUTICALS CORPORATION

  4/10/15 → 12/14/22

  Project: Research project

  • Arm 100%
  • Tisagenlecleucel T 50%
  • Diffuse Large B-Cell Lymphoma 50%
  • Patient 50%
  • Adult 50%

• A Randomized, Double-blind, Placebo-Controlled, Phase 2

  Geller, M. A.

  Morphotek, Inc.

  3/9/15 → 12/31/21

  Project: Research project

  • Placebo 100%
  • Blindness 100%
  • Farletuzumab 100%
  • Carboplatin 50%
  • Paclitaxel 50%

• Substernal Pacing Acute Clinical Evaluation (SPACE) Stud

  Roukoz, H.

  MEDTRONIC INC

  3/4/15 → 12/1/19

  Project: Research project

  • Evaluation 100%
  • Clinical Trial 100%

• A Phase 2, Open-Label, Single-Arm Study to Evaluate the

  Geller, M. A.

  TESARO, INC.

  3/3/15 → 9/1/20

  Project: Research project

  • Arm 100%
  • Primary Peritoneal Cancer 50%
  • Woman 50%
  • Niraparib 50%
  • Fallopian Tube 50%

• Randomised Evaluation of dabigatran etexilate Compared t

  Roukoz, H.

  BOEHRINGER-INGELHEIM PHARMACEUTICALS

  3/1/15 → 2/28/20

  Project: Research project

  • Evaluation Study 100%
  • Dabigatran Etexilate 100%
  • Anticoagulation 100%
  • Warfarin 50%
  • Pulmonary Vein Isolation 50%

• Cardiovascular Outcomes Assessment of the MitraClip Perc

  Helmer, G. A. & Das, G. S.

  ABBOTT VASCULAR SOLUTIONS INC

  2/23/15 → 10/1/21

  Project: Research project

  • Outcome Assessment 100%
  • Cardiovascular System 100%
  • Combination Therapy 50%
  • Patient 50%
  • Mitral Insufficiency 50%

• A Phase I/II safety, pharmacokinetic and pharmacodynamic

  Greeno, E. W.

  ANAEROPHARMA SCIENCE, INC

  2/3/15 → 2/28/21

  Project: Research project

  • Pharmacodynamics 100%
  • Pharmacokinetics 100%
  • Maltose 50%
  • Solid Malignant Neoplasm 50%
  • Flucytosine 50%

• Phase I Study to Evaluate the Safety, Tolerability and E

  Fujioka, N.

  MEDIMMUNE, LLC

  2/1/15 → 11/30/21

  Project: Research project

  • Tolerability 100%
  • Tremelimumab 100%
  • Squamous Cell Carcinoma 50%
  • Durvalumab 50%

• HM2014-26 DT2219 immunotoxin for the treatment of relaps

  Bachanova, V.

  GT BIOPHARMA, INC

  12/19/14 → 12/30/20

  Project: Research project

  • Immunotoxin 100%
  • Leukemia 50%
  • Lymphoma 50%

• HeartMate III IDE Clinical Study Protocol

  John, R.

  THORATEC INC

  12/1/14 → 12/31/21

  Project: Research project

  • Clinical Study 100%

• A Randomized, Multicenter, Open Label Study of MM-302 pl

  Blaes, A. H.

  MERRIMACK PHARMACEUTICALS, INC.

  11/30/14 → 11/30/19

  Project: Research project

  • Trastuzumab 100%
  • Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer 50%
  • Anthracycline 50%
  • Chemotherapy 50%
  • Breast 50%

• World-wide Randomized Antibiotic Envelope Infection Prev

  Adkisson, W. O.

  MEDTRONIC INC

  11/15/14 → 12/30/19

  Project: Research project

  • Infection 100%
  • Antibiotics 100%

• An open label Phase I dose escalation study to evaluate

  Geller, M. A.

  BAYER HEALTHCARE PHARMACEUTICALS

  10/8/14 → 12/1/14

  Project: Research project

  • Antibody Drug Conjugate 100%
  • Tolerability 100%
  • Solid Malignant Neoplasm 100%
  • Maximum Tolerated Dose 100%
  • Pharmacodynamics 100%

• A multicenter, Randomized, Open-Label Phase 3 Study to I

  Skubitz, K.

  CYTRX

  9/16/14 → 12/31/18

  Project: Research project

  • Aldoxorubicin 100%

• A Multicenter, International, Phase 3, Double-Blind, Pla

  Cogswell, R. J.

  PFIZER, INC.

  9/10/14 → 9/9/21

  Project: Research project

  • Blindness 100%
  • Placebo 50%
  • Tolerability 50%
  • Tafamidis 50%

• University of Pittsburgh Clinical and Translational Scie

  Delaney, C. W.

  UNIVERSITY OF PITTSBURGH, NATIONAL INSTITUTES OF HEALTH (NIH)

  9/1/14 → 6/30/15

  Project: Research project

• An Open-Label Extension Study of De-immunized DI-Leu16-I

  Bachanova, V.

  ALOPEXX ONCOLOGY LLC

  9/1/14 → 9/30/19

  Project: Research project

  • Nonhodgkin Lymphoma 100%
  • Immunocytokine 100%

• Prevention of HeartMate II Pump Thrombosis through Clini

  Thenappan, T. & Adatya, S. N.

  THORATEC INC

  8/19/14 → 6/30/17

  Project: Research project

  • Thrombosis 100%
  • Pump 100%
  • Clinical Management 50%

• REPRISE III: Repositionable Percutaneous Replacement of

  Helmer, G. A.

  BOSTON SCIENTIFIC CORPORATION

  8/1/14 → 8/31/22

  Project: Research project

  • Percutaneous Aortic Valve 100%
  • Clinical Trial 100%
  • Aortic Valve 100%

• A Phase 2, Dose-Ranging, Randomized, Double-Blind,Placeb

  Thenappan, T.

  GILEAD SCIENCES, INC.

  7/25/14 → 7/24/19

  Project: Research project

  • Blindness 100%
  • Placebo-Controlled Study 50%
  • Pulmonary Hypertension 50%